Fusion Capsid Therapy for COVID-19 and Applies to Other Viruses: Universal "Dominant" Antiviral to Prevent Virus Evolution and Future Pandemics (DNA/RNA/Protein)
Invention type: Technology, Tangible Property
/
Case number: #22801MH
Researchers
Departments: Department of Brain and Cognitive Sciences, Office of the Institute Professors, McGovern Institute for Brain Research, Department of Chemical Engineering
Technology Areas: Chemicals & Materials: Nanotechnology & Nanomaterials, Polymers / Drug Delivery: Microparticles & Nanoparticles, Vectors & Virus like Particles / Therapeutics: Nucleic Acids
Impact Areas: Healthy Living
-
compositions and methods for dominant antiviral therapy
European Patent Convention | Pending -
compositions and methods for dominant antiviral therapy
United States of America | Pending
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.